SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome
Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.
Video navigation menu
- Cardiovascular consequences of diabetes and diabetic kidney disease 00:43
- Effect of glucose lowering on diabetic late complications 02:43
- Lessons from EMPA REG Outcome 05:30
- Clinical implications of SGLT2 inhibition - as important as RAAS inhibition? 09:58
This lecture was part of a CME accredited symposium: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach held at Heart Failure 2017 in Paris.
- Emphasize heart failure as a disease in which innovation is ongoing, yielding several new agents that are soon likely to change clinical practice
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and heart failure and the particular risk of patients with diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
- To provide an expert perspective on the role of SGLT2 inhibitors in the treatment of patients with diabetes and heart failure
- To discuss current and future strategies for practical management of heart failure and interventions to prevent cardiovascular events
Professor Per-Henrik Groop is currently a Professor of Nephrology (Chair) at the University of Helsinki, Chief Physician at the Division of Nephrology, Helsinki University Central Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland.
This EBAC accredited symposium was funded by an unrestricted educational grant received from Boehringer-Ingelheim/Lilly